ArticleNPJ vaccines2025
Systematic review of evidence on feasibility of administering intranasal live attenuated influenza vaccine at home.
Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the United States, influenza vaccination coverage in adults and children remains below target, with disparities across racial and ethnic groups and setting urbanicity. Reducing barriers to influenza vaccination may improve coverage. Live attenuated influenza vaccine (LAIV) recently gained United States Food and Drug Administration approval for a Supplemental Biologics License for self- or caregiver administration. A systematic literature search of Embase and Medline (PubMed) was conducted on March 6, 2025. Of the 144 articles identified and reviewed for relevance, five articles reported effectiveness, safety, practicality, or preference data for self- or caregiver administration of LAIV (SA-LAIV). In the relevant studies, SA‑LAIV appeared to have comparable safety and effectiveness to healthcare professional-administered LAIV and was often the preferred method of vaccine administration by patients. At-home annual influenza vaccination may be a better option for some individuals and families, which could improve vaccination accessibility.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.